Abstract: The present invention relates to new compounds of formula (I) wherein Y, P, R1, R2, R3, n, m are defined as in claim 1, a process for their preparation and new intermediates used therein, pharmaceutical composition containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related disease, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3

Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Abstract: Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

Abstract: Granule formulations of quetiapine and pharmaceutically acceptable salts thereof are described, as are their preparation and their use in treating diseases of the central nervous system such as psychotic disease conditions including schizophrenia.

Abstract: Disclosed are thyroid hormone preparations useful in pharmaceutical applications. These preparations are disclosed to contain thyroxine drugs in combination with an inorganic salt, a carbohydrate having a molecular weight of greater than 500, and glycine. The preparations are also disclosed to have a free water content less than 4.5% by weight of the preparation. Also provided are compositions containing a reduced carbohydrate, a water soluble polysaccharide, or galactose. The preparations have improved stability wherein they are provided as being stable to the extent that substantially no potency loss is measured when the preparation is stored at 40.degree. C. and 75% relative humidity for 3 months.

Abstract: Food compositions and methods are provided for non-fat and low-fat food compositions containing a polyvinylpyrrolidone. The food compositions contain polyvinylpyrrolidone and other ingredients such as food stabilizers. Preferred compositions are non-fried foods, which include diary products, baked goods, salad dressings, and meat products. Specific food compositions include ice cream, muffins and pourable salads.

Abstract: Disclosed are thyroid hormone preparations useful in pharmaceutical applications. These preparations are disclosed to contain thyroxine drugs in combination with an inorganic salt, a carbohydrate having a molecular weight of greater than 500, and glycine. The preparations are also disclosed to have a free water content less than 4.5% by weight of the preparation. Also provided are compositions containing a reduced carbohydrate, a water soluble polysaccharide, or galactose. The preparations have improved stability wherein they are provided as being stable to the extent that substantially no potency loss is measured when the preparation is stored at 40.degree. C. and 75% relative humidity for 3 months.

Abstract: Provided are compositions and methods of improving a plant growth factor. The compositions and methods contain combinations of plant growth regulators such as plant growth retardants and inhibitors of ethylene biosynthesis or action. The ethylene inhibitors comprise substituted oxime-ethers having the general formula: ##STR1## where R1 and R2 independently of one another are C1-C6-alkyl, n is 2 or 3 and R3 is hydrogen or C1-C6-alkyl. Specific inhibitors of ethylene biosynthesis or action include: {?(isopropylidene)-amino!oxy}-acetic acid-2-(methoxy)-2-oxoethyl ester, {?(isopropylidene)-amino!oxy}-acetic acid-2-(hexyloxy)-2-oxoethyl ester, {{cyclohexylidene)-amino!oxy}-acetic acid-2-(isopropyloxy)-2-oxyethyl ester (methoxy)-2-oxoethyl ester, ?((isopropylidene)-amino!oxy acetic acid, aminooxyacetic acid, aminoethoxyvinylglycine, rhizobitoxine, silver ions (e.g. silver thiosulfate), and 2,5-norbornadiene.

Abstract: Provided herein is a plant growth regulator formulation comprising a plant growth regulator dispersed in polyvinyl alcohol ("PVA") particles having a mean diameter greater than 1 micron. The present invention also includes an emulsion containing an aqueous dispersion of PVA encapsulated plant growth regulator particles wherein said particles have a mean diameter greater than 1 micron. The above formulations are useful in methods of improving a plant growth factor in a plant.

Abstract: Provided herein is a plant growth regulator formulation comprising a plant growth regulator dispersed in polyvinyl alcohol ("PVA") particles having a mean diameter greater than 1 micron. The present invention also includes an emulsion containing an aqueous dispersion of PVA encapsulated plant growth regulator particles wherein said particles have a mean diameter greater than 1 micron. The above formulations are useful in methods of improving a plant growth factor in a plant.

Abstract: The method of the invention provides for improvement of a plant growth factor by applying an ethylene inhibitor plant growth regulator to a plant, such as cotton or soybean, at a low rate. Specific plant growth regulators include compounds covered by the general formula: ##STR1## where R1 and R2 independently of one another are C1-C6-alkyl, n is 2 or 3 and R3 is hydrogen or C1-C6 alkyl. Specific compounds employed by the method of the invention include {?(isopropylidene)-amino!oxy}-acetic acid-2-(methoxy)-2-oxoethyl ester, {?(isopropylidene)-amino!oxy}-acetic acid-2-(hexyloxy)-2-oxoethyl ester, {{cyclohexylidene)-amino!oxy}-acetic acid-2-(isopropyloxy)-2-oxoethyl ester, ?((isopropylidene)amino!oxy acetic acid and aminooxyacetic acid.

Abstract: Provided herein is a composition, system and method containing a hydrophobic lubricant and a water soluble solvent. The invention my also contain water. Specific solvents include akyl or alkoxy pyrrolidones such N-methyl-2-pyrrolidone which are added to or mixed with loom lubricators. Also provided is a method for inhibiting the increase in viscosity of lubricants used in polyolefin processing methods. Polyolefin compounds such as polyethylene, polypropylene and polybutylene are some of the compounds used in the invention. Provided are solutions, methods and systems used in manufacturing process that use polyolefins. The manufacturing processes include weaving, extruding and molding.

Abstract: Liposomes of a size of less than 200 nanometers target ischemic myocardial tissue and preferentially deliver active agents to infarcted areas in the absence of antibodies bound to the liposomes to effect the delivery.

Abstract: Delivery vehicle formulations comprising active agents encapsulated within microparticles which include a succinimidyl moiety extending externally from a lipid molecule therein are capable of the cytoplasmic or nuclear cell delivery of intact encapsulated active agents.

Abstract: Adhesions in synovial capsules are prevented through the administration of liposome intercalated nonsteroidal anti-inflammatory agents.

Abstract: Delivery vehicle formulations comprise active agents encapsulated within liposomal vesicles to which are attached protein hormones (ligands) such as interleukin-2. The ligands are capable of showing affinity for specific cell receptors resulting in delivery of the encapsulated active agent to target cells, enabling delivery of active agents to particular cell populations in the treatment of conditions such as immune system disorders.